
Cancer-specific stats 2024





## Snapshot of incidence, mortality and survival estimates by cancer type\*

| Dath saves sambined              | Incidence |         |               |       | Mortality | Survival      |            |
|----------------------------------|-----------|---------|---------------|-------|-----------|---------------|------------|
| Both sexes combined              | Rank      | Cases   | Trend         | Rank  | Deaths    | Trend         | 5-year (%) |
| All cancers                      | _         | 247,100 | $\downarrow$  | _     | 88,100    | $\downarrow$  | 64         |
| Lung and bronchus                | 1         | 32,100  | $\downarrow$  | 1     | 20,700    | $\downarrow$  | 22         |
| Breast                           | 2         | 30,800  | $\downarrow$  | 4     | 5,500     | <b>↓</b>      | 89         |
| Prostate                         | 3         | 27,900  | $\rightarrow$ | 5     | 5,000     | $\downarrow$  | 91         |
| Colorectal                       | 4         | 25,200  | $\downarrow$  | 2     | 9,400     | $\downarrow$  | 67         |
| Bladder                          | 5         | 12,300  | $\downarrow$  | 9,10  | 2,600     | $\downarrow$  | 77         |
| Non-Hodgkin lymphoma             | 6         | 11,700  | $\rightarrow$ | 8     | 3,100     | $\downarrow$  | 69         |
| Melanoma                         | 7         | 11,300  | <b>↑</b>      | 18    | 1,300     | $\downarrow$  | 89         |
| Kidney and renal pelvis          | 8         | 9,000   | <b>↑</b>      | 15    | 1,950     | <b>↓</b>      | 73         |
| Uterus (body, NOS)               | 9         | 8,600   | <b>↑</b>      | 17    | 1,600     | <b>↑</b>      | 82         |
| Head and neck                    | 10        | 8,100   | <b>↑</b>      | 12    | 2,100     | $\rightarrow$ | 64         |
| Pancreas                         | 11        | 7,100   | <b>↑</b>      | 3     | 6,100     | $\rightarrow$ | 10         |
| Thyroid                          | 12,13     | 6,600   | $\downarrow$  | 21    | 280       | $\rightarrow$ | 97         |
| Leukemia                         | 12,13     | 6,600   | $\downarrow$  | 7     | 3,200     | <b>↓</b>      | 61         |
| Liver and intrahepatic bile duct | 14        | 4,700   | $\rightarrow$ | 6     | 3,700     | 1             | 18         |
| Multiple myeloma                 | 15        | 4,100   | <b>↑</b>      | 16    | 1,750     | $\downarrow$  | 50         |
| Stomach                          | 16        | 4,000   | $\downarrow$  | 13,14 | 2,000     | $\downarrow$  | 29         |
| Brain/CNS                        | 17        | 3,300   | $\downarrow$  | 9,10  | 2,600     | $\rightarrow$ | 22         |
| Ovary                            | 18        | 3,000   | $\downarrow$  | 13,14 | 2,000     | <b>↓</b>      | 44         |
| Esophagus                        | 19        | 2,700   | $\rightarrow$ | 11    | 2,500     | $\downarrow$  | 16         |
| Soft tissue (including heart)    | 20        | 1,700   | $\rightarrow$ | 19    | 660       | <b>↑</b>      | 61         |
| Cervix                           | 21        | 1,600   | <b>↑</b>      | 20    | 400       | $\downarrow$  | 74         |
| Testis                           | 22        | 1,300   | <b>↑</b>      | 23    | 30        | $\downarrow$  | 97         |
| Hodgkin lymphoma                 | 23        | 1,200   | $\downarrow$  | 22    | 110       | $\downarrow$  | 85         |
| All other cancers                | NA        | 22,100  | <b>↑</b>      | NA    | 9,600     | $\rightarrow$ | NA         |

CNS=central nervous system; NOS=not otherwise specified; NA=not applicable

\*Source: Projected estimates of cancer in Canada in 2024 (Tables 1 and 2) available through cancer.ca/statistics and trend and survival estimates are from Canadian Cancer Statistics 2023 (Tables 1.7, 2.7 and 3.1). Both are available through cancer.ca/statistics and are accompanied by details on the data sources and methods used to obtain the estimates. Please reference accordingly. Email any questions to stats@cancer.ca.

| Cases    | Projected number of cancer diagnoses in Canada in 2024 (based on data to 2019)   |
|----------|--|
| Deaths   | Projected number of cancer deaths in Canada in 2024 (based on data to 2020)  |
| Rank     | Relative ranking of the 23 cancers from highest (1) to lowest (23) projected cases or deaths in 2024   |
| Survival | Predicted 5-year net survival for cases diagnosed in 2015—2017, Canadian Cancer Statistics 2023  |
| Trend    | Direction of most recent trend in incidence or mortality rate using data from 1984 to 2019; reflects statistically significant increase ( $\uparrow$ ) or decrease ( $\downarrow$ ) or no change ( $\rightarrow$ ) |

New: Canadian Cancer Statistics Dashboard presents the above cancer statistics in a new user-friendly format with interactive visualizations.

When using any of the above statistics, the following reference is recommended: Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2024. Toronto, ON: Canadian Cancer Society; 2024.

Cancer-specific stats 2024





## Snapshot of incidence, mortality and survival estimates by cancer type, males\*

| Males                            | Incidence |         |               |       | Survival |               |            |
|----------------------------------|-----------|---------|---------------|-------|----------|---------------|------------|
| Wates                            | Rank      | Cases   | Trend         | Rank  | Deaths   | Trend         | 5-year (%) |
| All cancers                      | _         | 127,100 | $\downarrow$  | _     | 47,300   | <b>↓</b>      | 62         |
| Prostate                         | 1         | 27,900  | $\rightarrow$ | 3     | 5,000    | $\downarrow$  | 91         |
| Lung and bronchus                | 2         | 14,800  | $\downarrow$  | 1     | 10,900   | $\downarrow$  | 19         |
| Colorectal                       | 3         | 14,100  | $\downarrow$  | 2     | 5,300    | $\downarrow$  | 66         |
| Bladder                          | 4         | 9,300   | $\downarrow$  | 6,7   | 1,900    | $\downarrow$  | 77         |
| Non-Hodgkin lymphoma             | 5         | 6,600   | $\rightarrow$ | 9     | 1,800    | <b>↓</b>      | 68         |
| Melanoma                         | 6         | 6,500   | 1             | 15    | 850      | <b>↓</b>      | 86         |
| Kidney and renal pelvis          | 7         | 5,900   | 1             | 12,13 | 1,250    | $\downarrow$  | 73         |
| Head and neck                    | 8         | 5,800   | 1             | 10    | 1,550    | $\rightarrow$ | 64         |
| Leukemia                         | 9         | 4,000   | $\downarrow$  | 8     | 1,850    | <b>↓</b>      | 60         |
| Pancreas                         | 10        | 3,800   | 1             | 4     | 3,200    | $\rightarrow$ | 10         |
| Liver and intrahepatic bile duct | 11        | 3,300   | $\rightarrow$ | 5     | 2,300    | $\rightarrow$ | 19         |
| Stomach                          | 12        | 2,600   | $\downarrow$  | 12,13 | 1,250    | $\downarrow$  | 27         |
| Multiple myeloma                 | 13        | 2,400   | 1             | 14    | 1,000    | $\downarrow$  | 50         |
| Esophagus                        | 14        | 2,100   | $\rightarrow$ | 6,7   | 1,900    | $\downarrow$  | 16         |
| Thyroid                          | 15        | 2,000   | $\rightarrow$ | 17    | 130      | <b>↑</b>      | 95         |
| Brain/CNS                        | 16        | 1,850   | $\rightarrow$ | 11    | 1,500    | $\rightarrow$ | 21         |
| Testis                           | 17        | 1,300   | <b>↑</b>      | 20    | 30       | $\downarrow$  | 97         |
| Soft tissue (including heart)    | 18        | 960     | $\rightarrow$ | 16    | 360      | <u></u>       | 60         |
| Hodgkin lymphoma                 | 19        | 650     | 1             | 18    | 75       | $\downarrow$  | 84         |
| Breast                           | 20        | 290     | 1             | 19    | 60       | $\downarrow$  | 76         |
| All other cancers                | NA        | 11,000  | <b>↑</b>      | NA    | 5,200    | $\rightarrow$ | NA         |

 ${\it CNS=central\ nervous\ system;\ NOS=not\ otherwise\ specified;\ NA=not\ applicable}$ 

\*Source: Projected estimates of cancer in Canada in 2024 (Tables 1 and 2) available through cancer.ca/statistics and trend and survival estimates are from Canadian Cancer Statistics 2023 (Tables 1.7, 2.7 and 3.1). Both are available through cancer.ca/statistics and are accompanied by details on the data sources and methods used to obtain the estimates. Please reference accordingly. Email any questions to <a href="mailto:stats@cancer.ca">stats@cancer.ca</a>.

| Cases    | Projected number of cancer diagnoses in Canada in 2024 (based on data to 2019)   |
|----------|--|
| Deaths   | Projected number of cancer deaths in Canada in 2024 (based on data to 2020)  |
| Rank     | Relative ranking of the 20 cancers from highest (1) to lowest (20) projected cases or deaths in 2024   |
| Survival | Predicted 5-year net survival for cases diagnosed in 2015—2017, Canadian Cancer Statistics 2023  |
| Trend    | Direction of most recent trend in incidence or mortality rate using data from 1984 to 2019; reflects statistically significant increase ( $\uparrow$ ) or decrease ( $\downarrow$ ) or no change ( $\rightarrow$ ) |

New: Canadian Cancer Statistics Dashboard presents the above cancer statistics in a new user-friendly format with interactive visualizations.

When using any of the above statistics, the following reference is recommended: Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2024. Toronto, ON: Canadian Cancer Society; 2024.





## Cancer-specific stats 2024

## Snapshot of incidence, mortality and survival estimates by cancer type, females\*

| Fameles                          | Incidence |         |               |      | Survival |               |            |
|----------------------------------|-----------|---------|---------------|------|----------|---------------|------------|
| Females                          | Rank      | Cases   | Trend         | Rank | Deaths   | Trend         | 5-year (%) |
| All cancers                      | _         | 120,000 | $\rightarrow$ | _    | 40,800   | $\downarrow$  | 66         |
| Breast                           | 1         | 30,500  | $\downarrow$  | 2    | 5,500    | $\downarrow$  | 89         |
| Lung and bronchus                | 2         | 17,300  | $\downarrow$  | 1    | 9,800    | $\downarrow$  | 26         |
| Colorectal                       | 3         | 11,100  | $\downarrow$  | 3    | 4,200    | $\downarrow$  | 67         |
| Uterus (body, NOS)               | 4         | 8,600   | 1             | 6    | 1,600    | 1             | 82         |
| Non-Hodgkin lymphoma             | 5         | 5,100   | $\rightarrow$ | 9    | 1,300    | $\downarrow$  | 71         |
| Melanoma                         | 6         | 4,800   | 1             | 17   | 440      | $\downarrow$  | 92         |
| Thyroid                          | 7         | 4,700   | $\downarrow$  | 20   | 150      | $\rightarrow$ | 98         |
| Pancreas                         | 8         | 3,300   | 1             | 4    | 2,900    | $\downarrow$  | 9          |
| Kidney and renal pelvis          | 9         | 3,100   | 1             | 14   | 670      | $\downarrow$  | 73         |
| Bladder                          | 10,11     | 3,000   | $\downarrow$  | 12   | 740      | $\downarrow$  | 75         |
| Ovary                            | 10,11     | 3,000   | $\downarrow$  | 5    | 2,000    | $\downarrow$  | 44         |
| Leukemia                         | 12        | 2,700   | $\downarrow$  | 7,8  | 1,350    | $\downarrow$  | 61         |
| Head and neck                    | 13        | 2,300   | <b>↑</b>      | 15   | 590      | $\downarrow$  | 65         |
| Multiple myeloma                 | 14        | 1,750   | 1             | 13   | 720      | $\downarrow$  | 51         |
| Cervix                           | 15        | 1,600   | <b>↑</b>      | 18   | 400      | $\downarrow$  | 74         |
| Liver and intrahepatic bile duct | 16        | 1,450   | $\downarrow$  | 7,8  | 1,350    | <b>↑</b>      | 17         |
| Stomach                          | 17,18     | 1,400   | $\downarrow$  | 11   | 760      | $\downarrow$  | 32         |
| Brain/CNS                        | 17,18     | 1,400   | $\downarrow$  | 10   | 1,100    | $\downarrow$  | 23         |
| Soft tissue (including heart)    | 19        | 730     | <b>↑</b>      | 19   | 300      | <b>↑</b>      | 62         |
| Esophagus                        | 20        | 630     | $\downarrow$  | 16   | 560      | $\downarrow$  | 17         |
| Hodgkin lymphoma                 | 21        | 530     | $\rightarrow$ | 21   | 40       | $\downarrow$  | 86         |
| All other cancers                | NA        | 11,200  | <b>↑</b>      | NA   | 4,400    | $\rightarrow$ | NA         |

CNS=central nervous system; NOS=not otherwise specified; NA=not applicable

\*Source: Projected estimates of cancer in Canada in 2024 (Tables 1 and 2) available through cancer.ca/statistics and trend and survival estimates are from Canadian Cancer Statistics 2023 (Tables 1.7, 2.7 and 3.1). Both are available through cancer.ca/statistics and are accompanied by details on the data sources and methods used to obtain the estimates. Please reference accordingly. Email any questions to <a href="mailto:stats@cancer.ca">stats@cancer.ca</a>.

| Cases    | Projected number of cancer diagnoses in Canada in 2024 (based on data to 2019)                                     |
|----------|--|
| Deaths   | Projected number of cancer deaths in Canada in 2024 (based on data to 2020)  |
| Rank     | Relative ranking of the 21 cancers from highest (1) to lowest (21) projected cases or deaths in 2024               |
| Survival | Predicted 5-year net survival for cases diagnosed in 2015—2017, Canadian Cancer Statistics 2023                    |
| Trend    | Direction of most recent trend in incidence or mortality rate using data from 1984 to 2019; reflects statistically |
|          | significant increase ( $\uparrow$ ) or decrease ( $\downarrow$ ) or no change ( $ ightarrow$ )                     |

New: Canadian Cancer Statistics Dashboard presents the above cancer statistics in a new user-friendly format with interactive visualizations.

When using any of the above statistics, the following reference is recommended: Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2024. Toronto, ON: Canadian Cancer Society; 2024.